NAPLEX Quiz: Drug Shortages And Biosimilars

What this quiz covers

This quiz focuses on Drug Shortages And Biosimilars, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Cefepime 2 g intravenously every 8 hours plus azithromycin 500 mg intravenously daily
2. Ampicillin/sulbactam 3 g intravenously every 6 hours plus azithromycin 500 mg intravenously daily (correct answer)
3. Ertapenem 1 g intravenously every 24 hours as monotherapy
4. Ciprofloxacin 400 mg intravenously every 12 hours as monotherapy

Explanation: This question tests the management of community-acquired pneumonia (CAP) during a ceftriaxone shortage, focusing on appropriate intravenous antibiotic alternatives per guidelines. The key patient-specific factors are type 2 diabetes, chronic kidney disease stage 3 with creatinine clearance of 45 mL/min, and the need for inpatient IV therapy. Ampicillin/sulbactam 3 g IV every 6 hours plus azithromycin 500 mg IV daily is the best choice because it provides broad-spectrum coverage similar to ceftriaxone plus azithromycin, is guideline-recommended for non-ICU CAP, and does not require renal dose adjustment for this creatinine clearance. Cefepime plus azithromycin is suboptimal as cefepime is typically reserved for hospital-acquired pneumonia and requires renal adjustment; ertapenem monotherapy lacks atypical coverage and is not first-line for CAP; ciprofloxacin monotherapy is inappropriate for severe CAP requiring IV therapy and has limited pneumococcal activity. Prednisone 40 mg orally daily for 5 days is incorrect as it addresses a different shortage scenario unrelated to antibiotics. A clinical pearl is that during beta-lactam shortages, prioritize alternatives with similar spectra and adjust for renal function to avoid toxicity. Pharmacists should collaborate with prescribers to select evidence-based regimens and monitor for efficacy.

Question 2

1. Switch to infliximab-dyyb at the same dose (5 mg/kg) and interval, then monitor for loss of response and infusion reactions (correct answer)
2. Switch to infliximab-dyyb and increase the dose to 10 mg/kg to prevent immunogenicity
3. Substitute adalimumab biosimilar at an equivalent mg dose without prescriber notification
4. Do not switch because biosimilars cannot be used for Crohn disease unless the product is labeled as interchangeable

Explanation: This question tests the principles of switching to a biosimilar for infliximab in Crohn disease, emphasizing safe substitution practices. The key patient-specific factor is stable disease on reference infliximab 5 mg/kg every 8 weeks, with no history of immunogenicity or adverse reactions. Switching to infliximab-dyyb at the same dose and interval with monitoring for loss of response and infusion reactions is the best approach because biosimilars are highly similar with no clinically meaningful differences, and guidelines support switching in stable patients with close follow-up. Increasing the dose to 10 mg/kg is unnecessary and increases risk of adverse effects without evidence of benefit; substituting adalimumab requires prescriber approval and is not equivalent; biosimilars can be used for Crohn disease regardless of interchangeability status. Double the dose for the first month is incorrect as it pertains to a different misconception. A transferable pearl is that biosimilar switches should maintain the same regimen and include patient education on reporting changes in efficacy or safety. Always document the specific product for traceability in case of adverse events.

Question 3

1. Dispense warfarin 10 mg tablets and instruct the patient to take 1 tablet daily
2. Dispense warfarin 2 mg tablets and instruct the patient to take 2.5 tablets daily
3. Dispense warfarin 2 mg tablets and instruct the patient to take 2 tablets plus half of a 2 mg tablet daily (total 5 mg), with clear written directions (correct answer)
4. Avoid warfarin and discontinue anticoagulation until 5 mg tablets are available

Explanation: This question tests the management of warfarin dosing during a tablet strength shortage, emphasizing safe dispensing to achieve the prescribed dose. The key patient-specific factor is the need for a precise 5 mg daily dose for pulmonary embolism bridging, with available 2 mg and 10 mg tablets. Dispensing 2 mg tablets and instructing to take 2 tablets plus half of a 2 mg tablet daily (total 5 mg) with clear written directions is best because it accurately delivers the dose while minimizing confusion through explicit guidance. Using 10 mg tablets for 1 daily is overdosing; instructing 2.5 tablets without specifying halving may lead to errors; discontinuing anticoagulation risks thrombosis. Expecting less effectiveness is unrelated to warfarin. A clinical pearl is to provide visual aids or pill cutters for split doses during shortages to enhance adherence and safety. Always verify patient understanding and monitor INR closely after changes.

Question 4

1. Expect the biosimilar to be less effective because it is not identical to the reference product
2. Use the new product exactly as prescribed, and report any new injection-site reactions or loss of symptom control after the switch (correct answer)
3. Double the dose for the first month to prevent antibody formation
4. Stop methotrexate when starting the biosimilar to reduce adverse effects

Explanation: This question tests patient counseling principles when switching to an adalimumab biosimilar in rheumatoid arthritis. The key patient-specific factor is stable disease on reference adalimumab with concomitant methotrexate, requiring education on potential subtle differences. Counseling to use the new product as prescribed and report new injection-site reactions or loss of symptom control is crucial because biosimilars are highly similar but switches may rarely affect tolerability or efficacy, necessitating monitoring. Expecting less effectiveness is incorrect as biosimilars demonstrate no clinically meaningful differences; doubling the dose is unnecessary and risky; stopping methotrexate increases flare risk without benefit. Switching to enalapril is unrelated to biologics. A transferable pearl is that biosimilar education should emphasize equivalence while encouraging vigilance for changes, with reporting to healthcare providers. Pharmacists play a key role in building patient confidence through clear communication.

Question 5

1. Dispense adalimumab-adbm in place of Humira only if the biosimilar is designated as interchangeable under state law; otherwise contact the prescriber for authorization (correct answer)
2. Automatically substitute any adalimumab biosimilar for Humira because all biosimilars are therapeutically equivalent
3. Substitute infliximab-dyyb at an equivalent dose because it is a biosimilar tumor necrosis factor inhibitor
4. Switch to etanercept 50 mg weekly without prescriber input because it is the same drug class

Explanation: This question tests understanding of biosimilar substitution regulations and the distinction between biosimilar and interchangeable products. The key regulatory factor is that biosimilars require specific FDA designation as "interchangeable" to be automatically substituted at the pharmacy level without prescriber authorization. The correct approach is to dispense adalimumab-adbm only if it has interchangeability designation and state law permits substitution; otherwise, prescriber authorization is required. Automatically substituting any biosimilar is incorrect because not all biosimilars are designated as interchangeable - they must meet additional FDA requirements demonstrating they can be switched back and forth with the reference product. Substituting a different TNF inhibitor like infliximab-dyyb or etanercept represents a therapeutic change requiring prescriber approval, not a simple substitution. The clinical pearl is that biosimilars without interchangeability designation require prescriber authorization before dispensing, even if they are the same active ingredient as the reference product.

Question 6

1. Interchange to rivaroxaban 20 mg by mouth twice daily for equivalent anticoagulation intensity
2. Interchange to dabigatran 150 mg by mouth twice daily without regard to administration with food and without counseling
3. Interchange to warfarin and immediately discontinue all anticoagulation until the international normalized ratio (INR) becomes therapeutic
4. Interchange to rivaroxaban 20 mg by mouth once daily with the evening meal (or another formulary direct oral anticoagulant at an appropriate dose) and ensure renal function and bleeding risk are assessed (correct answer)

Explanation: This question tests appropriate direct oral anticoagulant (DOAC) interchange during drug shortages. The key patient-specific factors are normal renal function and remote history of GI bleed, making her a candidate for standard-dose DOAC therapy. Rivaroxaban 20 mg once daily with food is the most appropriate interchange, providing equivalent stroke prevention in atrial fibrillation while considering formulary availability and proper administration requirements. Rivaroxaban 20 mg twice daily is the venous thromboembolism treatment dose, not the atrial fibrillation dose. Dabigatran requires renal function assessment and specific counseling about storage and GI effects. Warfarin interchange requires overlap with the DOAC until therapeutic INR is achieved, not immediate discontinuation. The clinical principle for DOAC interchange is to select an alternative at the appropriate indication-specific dose, ensure renal function supports the dose, and provide proper administration counseling (rivaroxaban with food for doses ≥15 mg).

Question 7

1. Explain that the biosimilar is expected to have no clinically meaningful differences in safety and effectiveness, but the product name and lot number should be recorded for pharmacovigilance (correct answer)
2. Advise that the biosimilar works through a different mechanism and may require a higher dose to maintain remission
3. Tell the patient to stop mesalamine immediately because it interacts with biosimilar infliximab
4. Counsel that infusion reactions cannot occur with biosimilars because they are purified versions of the originator

Explanation: This question tests understanding of biosimilar counseling points and pharmacovigilance requirements. The key concept is that biosimilars are highly similar to reference products with no clinically meaningful differences in safety and efficacy, but require specific documentation for tracking. The correct counseling emphasizes that the biosimilar is expected to work as effectively as the originator while highlighting the importance of recording the specific product name and lot number for pharmacovigilance purposes. Biosimilars work through the same mechanism as originators and do not require dose adjustments. There is no interaction between mesalamine and infliximab biosimilars. Biosimilars carry the same risk of infusion reactions as originator products. The clinical pearl is that while biosimilars are therapeutically equivalent, accurate documentation of the specific product dispensed is crucial for post-market surveillance and tracking any potential product-specific adverse events.

Question 8

1. Whether the biosimilar has an FDA interchangeability designation (and state law requirements for substitution and prescriber notification) (correct answer)
2. Whether any monoclonal antibody biosimilar can be substituted for ustekinumab because all biologics share the same mechanism
3. Whether the biosimilar is approved only for asthma, because Crohn disease is an off-label indication for ustekinumab
4. Whether switching requires doubling the ustekinumab dose for 2 cycles to prevent loss of response

Explanation: This question tests understanding of biosimilar interchangeability regulations and state-specific substitution requirements. The key regulatory factor is that biosimilar substitution at the pharmacy level requires both FDA interchangeability designation and compliance with state pharmacy laws regarding substitution and prescriber notification. Only biosimilars with specific FDA interchangeability designation can be automatically substituted, and states may have additional requirements for prescriber notification. Not all monoclonal antibody biosimilars can be substituted for each other - they must be biosimilars of the same reference product. Ustekinumab is FDA-approved for Crohn disease, not off-label use. Biosimilar switching does not require dose adjustments as they are highly similar to reference products. The clinical pearl is that pharmacists must verify both federal interchangeability designation and state-specific substitution laws before dispensing a biosimilar in place of a prescribed reference product.

Question 9

1. Whether the biosimilar is FDA-designated as interchangeable and whether state law permits pharmacist substitution (correct answer)
2. Whether the biosimilar has a lower wholesale acquisition cost, regardless of interchangeability status
3. Whether the biosimilar has a different mechanism of action than the reference product
4. Whether switching requires doubling the dose for the first two injections

Explanation: This question tests the factors for pharmacist-initiated substitution of biosimilars, such as for ustekinumab in psoriasis. The key patient-specific factor is maintenance on ustekinumab 45 mg every 12 weeks, with a request for substitution without prescriber involvement. Considering whether the biosimilar is FDA-designated as interchangeable and if state law permits substitution is essential because only interchangeable biosimilars can be pharmacist-substituted like generics, subject to state regulations. Lower cost alone does not allow substitution without interchangeability; biosimilars have the same mechanism; doubling the dose is not required. Vancomycin dosing is unrelated to biosimilars. A transferable pearl is that biosimilar substitution policies vary by product approval (biosimilar vs. interchangeable) and jurisdiction. Pharmacists should consult formularies and laws before dispensing to ensure compliance.

Question 10

1. Recommend prednisone 40 mg by mouth daily for 5 days instead of intravenous methylprednisolone (correct answer)
2. Recommend dexamethasone 1 mg by mouth daily for 5 days
3. Recommend hydrocortisone 10 mg intravenously every 8 hours for 48 hours
4. Hold systemic steroids and use only inhaled albuterol

Explanation: This question tests the management of systemic corticosteroids for COPD exacerbation during an intravenous methylprednisolone shortage. The key patient-specific factor is the ability to swallow oral medications, allowing transition from IV to equivalent oral therapy. Recommending prednisone 40 mg orally daily for 5 days is the best action because it provides equipotent anti-inflammatory effects (prednisone 40 mg ≈ methylprednisolone 32 mg) and guidelines support oral steroids for COPD exacerbations. Dexamethasone 1 mg is underdosed; hydrocortisone 10 mg IV every 8 hours is insufficient for exacerbation; holding steroids worsens outcomes. Cefazolin dosing is unrelated to steroids. A clinical pearl is to use glucocorticoid equivalency tables (e.g., prednisone 5 mg = methylprednisolone 4 mg) for conversions during shortages. Taper if prolonged use, and monitor for hyperglycemia in at-risk patients.

Question 11

1. Vancomycin 20 mg/kg intravenously every 8 hours (maximum 2 g per dose) until delivery (correct answer)
2. Cefazolin 2 g intravenously loading dose, then 1 g intravenously every 8 hours until delivery
3. Amoxicillin 500 mg by mouth every 8 hours until delivery
4. Azithromycin 500 mg intravenously daily until delivery

Explanation: This question tests intrapartum group B Streptococcus (GBS) prophylaxis alternatives during a clindamycin shortage in penicillin-allergic patients. The key patient-specific factor is anaphylaxis to penicillin, preterm premature rupture of membranes at 28 weeks, and lack of clindamycin susceptibility results. Vancomycin 20 mg/kg IV every 8 hours (max 2 g/dose) until delivery is the best choice because guidelines recommend it for high-risk penicillin allergy when clindamycin is unavailable, providing effective GBS coverage. Cefazolin risks cross-reactivity in anaphylaxis; oral amoxicillin is inadequate for intrapartum prophylaxis; azithromycin lacks reliable GBS activity. Dispensing 2 mg tablets is unrelated to antibiotics. A clinical pearl is to use weight-based dosing for vancomycin in pregnancy, monitoring levels if prolonged. During shortages, prioritize guideline alternatives and expedite susceptibility testing when possible.

Question 12

1. Recommend substituting abobotulinumtoxinA using a 1:1 unit conversion from onabotulinumtoxinA
2. Recommend not substituting because botulinum toxin products are not therapeutically equivalent on a unit-to-unit basis; prescriber must select and dose appropriately (correct answer)
3. Recommend switching to incobotulinumtoxinA at double the unit dose automatically
4. Recommend dispensing oral botulinum toxin tablets as an equivalent alternative

Explanation: This question tests the management of botulinum toxin product shortages in chronic migraine, focusing on non-equivalence. The key patient-specific factor is established dosing with onabotulinumtoxinA, requiring prescriber involvement for alternatives. Recommending not substituting because botulinum toxin products are not therapeutically equivalent on a unit-to-unit basis, so the prescriber must select and dose appropriately, is best to ensure safety and efficacy. Using 1:1 conversion risks under- or overdosing; doubling incobotulinumtoxinA is incorrect; oral botulinum is nonexistent. Administering standard-dose vaccine is unrelated to toxins. A clinical pearl is that botulinum toxins have unique potencies and indications, prohibiting automatic substitution. During shortages, explore compounding or alternative therapies with neurology input.

Question 13

1. Metoprolol 5 mg intravenously every 5 minutes as needed up to 15 mg, with monitoring of heart rate and blood pressure (correct answer)
2. Propranolol 10 mg intravenously every 6 hours scheduled
3. Epinephrine infusion titrated to heart rate control
4. Albuterol nebulizations every 4 hours to improve cardiac output

Explanation: This question tests rate control alternatives for atrial fibrillation with rapid ventricular response during a diltiazem shortage. The key patient-specific factor is asthma history, necessitating a cardioselective beta-blocker to minimize bronchoconstriction risk. Metoprolol 5 mg IV every 5 minutes as needed up to 15 mg with monitoring is the best alternative because it effectively controls heart rate and is guideline-recommended, with selectivity reducing asthma exacerbation risk. Propranolol is nonselective and contraindicated in asthma; epinephrine infusion risks tachyarrhythmias; albuterol does not control rate. Explaining biosimilar specificity is unrelated to rate control. A clinical pearl is to monitor vital signs closely during IV beta-blocker administration and have reversal agents ready. During shortages, select alternatives based on comorbidities like asthma to optimize safety.

Question 14

1. Omeprazole 20 mg by mouth daily
2. Omeprazole 40 mg by mouth daily (correct answer)
3. Famotidine 10 mg by mouth daily
4. Sucralfate 1 g by mouth once daily

Explanation: This question tests therapeutic alternatives for gastroesophageal reflux disease during a pantoprazole shortage, focusing on equipotent proton pump inhibitors. The key patient-specific factor is daily 40 mg pantoprazole dosing, requiring a comparable alternative for symptom control. Omeprazole 40 mg orally daily is the best choice because it provides equivalent acid suppression and is bioequivalent at this dose for GERD management. Omeprazole 20 mg is underdosed; famotidine 10 mg has lower potency as an H2 blocker; sucralfate is adjunctive, not a PPI substitute. The biosimilar has no differences is unrelated to PPIs. A clinical pearl is to use PPI equivalency (e.g., pantoprazole 40 mg = omeprazole 40 mg) for switches, monitoring for breakthrough symptoms. Counsel on timing with meals and long-term risks like bone health.

Question 15

1. Recommend switching to any biosimilar monoclonal antibody because they are all interchangeable within the class
2. Explain that biosimilars are product-specific; substitution depends on availability of an FDA-approved biosimilar for denosumab and interchangeability/state law (correct answer)
3. Advise her to split the denosumab dose in half and inject monthly to mimic a biosimilar
4. Tell her biosimilars are generics and can always be substituted without prescriber involvement

Explanation: This question tests the principles of biosimilar substitution for denosumab in osteoporosis, addressing patient inquiries on cost-saving options. The key patient-specific factor is stable therapy on denosumab 60 mg every 6 months, with no biosimilar currently approved for denosumab. Explaining that biosimilars are product-specific and substitution depends on FDA approval for a denosumab biosimilar and interchangeability/state law is most appropriate because biosimilars must reference the specific originator product and meet regulatory criteria. Substituting any monoclonal antibody is incorrect as they are not interchangeable across classes; splitting doses is unsafe; biosimilars are not generics. Cefixime dosing is unrelated to biologics. A transferable pearl is to check current FDA approvals for biosimilars, as availability evolves, and involve prescribers for non-interchangeable switches. Educate patients on the rigorous approval process to build trust in biosimilars.

Question 16

1. Cefazolin 2 g intravenously every 8 hours (correct answer)
2. Vancomycin 15 mg/kg intravenously every 12 hours
3. Ceftriaxone 1 g intravenously every 24 hours
4. Aztreonam 2 g intravenously every 8 hours

Explanation: This question tests therapeutic alternatives for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia during a nafcillin shortage. The key patient-specific factor is uncomplicated MSSA bacteremia requiring anti-staphylococcal beta-lactam therapy. Cefazolin 2 g IV every 8 hours is the best choice because it is guideline-recommended as an effective alternative to nafcillin for MSSA, with convenient dosing and good tolerability. Vancomycin is reserved for MRSA or allergy; ceftriaxone has higher failure rates in bacteremia; aztreonam lacks gram-positive coverage. Whether the biosimilar is interchangeable is unrelated to antibiotics. A clinical pearl is to prefer beta-lactams over vancomycin for MSSA due to superior outcomes. During shortages, monitor for treatment response and switch back to preferred agents when available.

Question 17

1. Administer standard-dose inactivated influenza vaccine today rather than delaying vaccination (correct answer)
2. Defer influenza vaccination until high-dose vaccine is available, even if after influenza season begins
3. Administer two standard-dose influenza vaccines at the same visit to equal one high-dose vaccine
4. Administer live attenuated influenza vaccine because it is more potent in older adults

Explanation: This question tests influenza vaccination strategies during a high-dose vaccine shortage in older adults. The key patient-specific factor is age 72 years with asthma and coronary artery disease, benefiting from any timely influenza vaccination. Administering standard-dose inactivated influenza vaccine today rather than delaying is best because ACIP recommends vaccinating with available products during shortages, as some protection is better than none. Deferring until high-dose availability risks exposure; administering two standard doses does not equate to high-dose; live vaccine is contraindicated in older adults and asthma. Meropenem dosing is unrelated to vaccines. A clinical pearl is that timely vaccination outweighs waiting for preferred formulations in high-risk groups. Counsel on revaccination if supply allows, but prioritize initial protection.

Question 18

1. Start semaglutide 1 mg subcutaneously once weekly immediately
2. Start semaglutide 0.25 mg subcutaneously once weekly and titrate per labeling to minimize gastrointestinal adverse effects (correct answer)
3. Switch to exenatide immediate-release 10 mcg subcutaneously once weekly
4. Stop GLP-1 receptor agonist therapy and increase metformin to 3000 mg/day

Explanation: This question tests GLP-1 receptor agonist alternatives during a dulaglutide shortage in type 2 diabetes. The key patient-specific factor is controlled disease on dulaglutide 1.5 mg weekly, requiring titration to minimize gastrointestinal side effects. Starting semaglutide 0.25 mg subcutaneously weekly and titrating per labeling is best because it allows gradual dose escalation similar to dulaglutide, maintaining glycemic control. Starting at 1 mg risks severe GI intolerance; exenatide IR requires BID dosing, less convenient; stopping GLP-1 and increasing metformin exceeds safe doses. Levalbuterol inhaler is unrelated to diabetes. A clinical pearl is to titrate GLP-1 agonists slowly (e.g., semaglutide: 0.25 mg x4 weeks, then 0.5 mg) to improve tolerability. Monitor A1c and weight, adjusting based on response during shortages.

Question 19

1. Levalbuterol inhaler 2 puffs every 4 to 6 hours as needed for shortness of breath (correct answer)
2. Salmeterol inhaler 2 puffs every 4 to 6 hours as needed for acute symptoms
3. Fluticasone inhaler 2 puffs every 4 to 6 hours as needed for acute symptoms
4. Ipratropium inhaler 2 puffs twice daily as needed for acute symptoms

Explanation: This question tests rescue inhaler alternatives during an albuterol shortage in asthma. The key patient-specific factor is as-needed use for shortness of breath, requiring a similar short-acting beta-agonist. Levalbuterol inhaler 2 puffs every 4 to 6 hours as needed is the best alternative because it is the active enantiomer of albuterol, providing equivalent bronchodilation with potentially fewer side effects. Salmeterol is long-acting, not for acute relief; fluticasone is a corticosteroid without rescue properties; ipratropium is an anticholinergic, slower onset for acute symptoms. Omeprazole 40 mg is unrelated to asthma. A clinical pearl is to reserve levalbuterol for patients with albuterol intolerance, but use it 1:1 during shortages. Educate on proper inhaler technique and when to seek emergency care.

Question 20

1. The biosimilar is expected to have no clinically meaningful differences in safety and effectiveness, but the name/manufacturer may differ for tracking (correct answer)
2. The biosimilar will require more frequent dosing because it is less potent
3. You should stop all chemotherapy for 2 weeks after switching to reduce interactions
4. Biosimilars are unregulated, so adverse effects cannot be reported

Explanation: This question tests counseling for switching to a bevacizumab biosimilar in metastatic colorectal cancer. The key patient-specific factor is ongoing therapy with reference bevacizumab plus chemotherapy, requiring reassurance on equivalence. Stating that the biosimilar is expected to have no clinically meaningful differences in safety and effectiveness, but the name/manufacturer may differ for tracking, is crucial because it addresses common concerns while emphasizing pharmacovigilance. Requiring more frequent dosing is false; stopping chemotherapy is harmful; biosimilars are FDA-regulated with adverse event reporting. Recommending not substituting botulinum is unrelated to oncology. A transferable pearl is to highlight biosimilar rigor in approval, encouraging reporting of any changes post-switch. Pharmacists should use product-specific identifiers in records for traceability.